BofA analyst Jason Gerberry lowered the firm’s price target on Organon to $19 from $23 and keeps an Underperform rating on the shares. The firm forecasts in-line Q3 sales and EBITDA, but flags potential downside risks to estimates, adding that it is “hard to see 3Q as a catalyst” for Organon.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OGN:
- Goldman Sachs Says These 2 Stocks Could Double Your Money — Here’s Why They Could Jump
- Organon initiated with an Overweight at Barclays
- Organon’s JADA System reaches efficacy endpoint in published study
- Organon appoints Juan Camilo Arjona Ferreira as CMO
- 3M names Carrie Cox as Chairman of new new Health Care company